<DOC>
	<DOCNO>NCT02341417</DOCNO>
	<brief_summary>This phase 3 , 32-week , multicenter , single arm , open-label extension study . All enrolled subject administer cinacalcet daily treatment period addition standard care treatment include therapy Vitamin D sterol , calcium supplementation , phosphate binder .</brief_summary>
	<brief_title>Single-arm Extension Study Safety Cinacalcet Treatment SHPT Pediatric Subjects With CKD Dialysis</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<mesh_term>Cinacalcet Hydrochloride</mesh_term>
	<criteria>INCLUSION CRITERIA : All subject : Subject 's legally acceptable representative provide informed consent subject legally young provide informed consent subject provide write assent base local regulation and/or guideline prior Study 20140159 activities/procedures initiate . Dialysate calcium concentration ≥ 2.5 mEq/L day 1 All subject &gt; 14 day last study visit Study 20130356 Study 20110100 screen Study 20140159 : • Subjects anticonvulsant medication must stable dose All subject 20130356 : Completed treatment week 20 20130356 study study time Study 20130356 termination Dry weight ≥ 12.5 kg day 1 Study 20140159 Subjects Randomized 20130356 Standard Care Arm Only : iPTH value ≥ 300 pg/mL ( within 7 day day 1 Study 20140159 ) Corrected calcium value ≥ 8.8 mg/dL within 7 day day 1 Study 20140159 All Subjects 20110100 : Completed week 26 End Study visit , 20110100 study study time Study 20110100 termination Dry weight ≥ 7 kg day 1 Study 20140159 EXCLUSION CRITERIA : General ( study 20130356 20110100 ) : Currently receive treatment another investigational device drug study , less 30 day since end treatment another investigational device drug study ( ) , Amgen Studies 20130356 20110100 . Other investigational procedure participate study exclude . Malignancy except nonmelanoma skin cancer , cervical breast ductal carcinoma situ within last 5 year . Subject know sensitivity product administer dosing . Subject likely available complete protocolrequired study visit procedure , and/or comply require study procedure ( eg , electronic patient diary [ ediary ] ) best subject investigator 's knowledge History evidence clinically significant disorder , condition disease ( exception outline ) , opinion investigator Amgen physician , consult , would pose risk subject safety interfere study evaluation , procedure , completion . Subject previously enter study . If sexually active , subject willing use acceptable contraception treatment least 9 day end treatment . Subject pregnant breast feeding , plan become pregnant study within 9 day end treatment History congenital long QT syndrome , second third degree heart block , ventricular tachyarrythmias , condition associate prolonged QT interval A new onset seizure worsen preexist seizure disorder All Subjects &gt; 14 day last study visit Study 20130356 Study 20110100 screen visit Study 20140159 follow exclusion criterion apply screen day 1 : Unstable chronic heart failure define worsen pulmonary edema sign symptom per investigator assessment screen Received therapy commercial cinacalcet last study visit Study 20130356 Study 20110100 day 1 Study 20140159 Scheduled date kidney transplantation know living donor make completion study unlikely Either new recurrent cardiac ventricular arrhythmia require change treatment within 10 day prior screen visit day 1 Study 20140159 screen Hepatic impairment indicate elevated level hepatic transaminase bilirubin ( aspartate aminotransferase [ AST ] ≥ 1.5 × upper limit normal [ ULN ] OR alanine aminotransferase [ ALT ] ≥ 1.5 × ULN OR total bilirubin ≥ 1 × ULN per institutional laboratory range ) screen All Subjects Day 1 Study Visit : Subject ongoing adverse event Studies 20130356 20110100 consider related IP ≥ CTCAE ( v 4.0 ) grade 3 , and/or consider clinically significant opinion investigator Central laboratory value obtained/are available day 1 Study 20140159 Corrected QT Interval ( QTc ) &gt; 500 m , use Bazett 's formula QTc ≥ 450 ≤ 500 m , use Bazett 's formula , unless write permission enroll provide investigator consultation pediatric cardiologist Use grapefruit juice , herbal medication , CYP3A4 inhibitor ( eg , erythromycin , clarithromycin , ketoconazole , itraconazole ) , CYP2D6 substrates ( eg , flecainide , propafenone , metoprolol , desipramine , nortriptyline , clomipramine ) Use concomitant medication may prolong QTc interval ( eg , ondansetron , albuterol )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Chronic Kidney Disease , Dialysis , Secondary Hyperparathyroidism , Pediatric</keyword>
</DOC>